Assoc Prof Philip Beale provides a summary of SOLO2’s findings, which were presented at ASCO 2020:
“After a median of 5.5 years of follow up, SOLO2 has shown a significant improvement in overall survival adding 12.9 months of life to those treated with olaparib. This also increased the time to subsequent treatment to 27.4 months compared with 7.2 months in the placebo arm.
This is a significant effect and confirming the importance of olaparib in the treatment of relapsed BRCA mutation-positive ovarian cancer.
Also, there are three Australian researchers listed in the sites participating and Prof Michael Friedlander AM as an author.”